570 related articles for article (PubMed ID: 10598693)
41. [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients].
Kałuzny JJ; Szaflik J; Czechowicz-Janicka K; Kałuzny J; Orzałkiewicz A; Zaleska-Zmijewska A; Krajewska M; Stewart JA; Leech JN; Stewart WC
Klin Oczna; 2004; 106(1-2 Suppl):241-2. PubMed ID: 15510513
[TBL] [Abstract][Full Text] [Related]
42. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study.
Francis BA; Du LT; Berke S; Ehrenhaus M; Minckler DS;
J Clin Pharm Ther; 2004 Aug; 29(4):375-80. PubMed ID: 15271105
[TBL] [Abstract][Full Text] [Related]
43. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
44. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
Chiseliţă D; Antohi I; Medvichi R; Danielescu C
Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
[TBL] [Abstract][Full Text] [Related]
45. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
Lass JH; Khosrof SA; Laurence JK; Horwitz B; Ghosh K; Adamsons I
Arch Ophthalmol; 1998 Aug; 116(8):1003-10. PubMed ID: 9715679
[TBL] [Abstract][Full Text] [Related]
46. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group.
Hutzelmann JE; Polis AB; Michael AJ; Adamsons IA
Acta Ophthalmol Scand; 1998 Dec; 76(6):717-22. PubMed ID: 9881560
[TBL] [Abstract][Full Text] [Related]
47. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
48. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
49. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
[TBL] [Abstract][Full Text] [Related]
50. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
Konstas AG; Mikropoulos D; Dimopoulos AT; Moumtzis G; Nelson LA; Stewart WC
Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549
[TBL] [Abstract][Full Text] [Related]
51. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
Maruyama K; Shirato S
J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
[TBL] [Abstract][Full Text] [Related]
52. A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study.
Simpson AJ; Gray TB; Ballantyne C
Aust N Z J Ophthalmol; 1996 Feb; 24(1):39-42. PubMed ID: 8743003
[TBL] [Abstract][Full Text] [Related]
53. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
[TBL] [Abstract][Full Text] [Related]
54. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
Baiza-Durán LM; Alvarez-Delgado J; Contreras-Rubio AY; Medrano-Palafox J; De Luca-Brown A; Casab-Rueda H; Cortés-Gastélum MA; Garcidueñas-Mejía MJ; Gómez-Bastar P; Gil-Carrasco F; Hartleben-Matkin C; Jiménez-Román J; Moreno-Marín ML; Paczka-Zapata JA; Velasco-Gallegos G; Vergara-Sinta M
Ann Ophthalmol (Skokie); 2009; 41(3-4):174-8. PubMed ID: 20214051
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
[TBL] [Abstract][Full Text] [Related]
56. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
57. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
[TBL] [Abstract][Full Text] [Related]
59. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
Coleman AL; Lerner F; Bernstein P; Whitcup SM
Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
[TBL] [Abstract][Full Text] [Related]
60. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Silver LH
Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]